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Abstract
Background: Coverage levels for many recommended adult vaccinations are low. The cost-
effectiveness research literature on adult vaccinations has not been synthesized in recent years, 
which may contribute to low awareness of the value of adult vaccinations and to their under-
utilization. We assessed research literature since 1980 to summarize economic evidence for adult 
vaccinations included on the adult immunization schedule.
Methods: We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 
and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting 
persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract 
reviews, the remaining publications had a full-text review from two independent reviewers, who 
extracted economic values that compared vaccination to “no vaccination” scenarios.
Results: The systematic searches yielded 1688 publications. After removing duplicates, off-topic 
publications, and publications without a “no vaccination” comparison, 78 publications were 
included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, 
herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). 
Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% 
for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. 
Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a 
cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human 
papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations.
Conclusions: The majority of published studies report favorable cost-effectiveness profiles for 
adult vaccinations, which supports efforts to improve the implementation of adult vaccination 
recommendations.
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1. Introduction
The Advisory Committee on Immunization Practices (ACIP) recommends vaccinations for 
adults in the U.S. based on their age, medical conditions, and prior vaccinations as part of 
the U.S. immunization schedule for routine vaccination of adults [1]. Vaccines commonly 
administered to adults include influenza, pneumococcal, herpes zoster (HZ), tetanus-
diphtheria/tetanus-dip htheria-acellular pertussis (Td/Tdap), and hepatitis B vaccines. The 
burden of disease among adults, including illness, hospitalization, death and disability, from 
vaccine preventable diseases (VPDs) is substantial [2]. However, vaccination coverage rates 
for many routinely-recommended adult vaccines are low [3]. Missed opportunities for adult 
vaccinations contribute to an overall disease burden that was estimated at $26.5 billion 
among persons aged 50 years and older for four common VPDs: influenza, pneumococcal 
disease, HZ, and pertussis [4].
Among the many challenges that exist for implementation of the adult vaccinations [5–8], 
potential reasons for lower than expected adult vaccination coverage rates could be 
perceptions about risks, clinical value, and economic value held by providers [9] or patients 
[10]. Value perceptions may be especially important among providers since provider 
recommendations substantially contribute to patients’ decisions regarding vaccination [11]. 
To date, reviews of cost-effectiveness analyses of adult immunization services have focused 
onjust one vaccine at a time [12–16], such as vaccines for HZ [12,14], influenza [13,16], or 
human papillomavirus (HPV) [15], or specific target populations, such as healthcare 
personnel [16]. Reviews that focus on specific vaccines can be useful to investigate 
modeling choices that contribute to variations in results across models. A review that is 
broader in scope is needed to address other types of questions that may be of interest to 
clinicians and policy makers. These kinds of questions are related to how the cost-
effectiveness of a given vaccine compares to other vaccines that also are recommended for a 
similar age group or a similar target population and, taken a step further, how the cost-
effectiveness of vaccines in general relates to other clinical services. Prior cost-effectiveness 
analyses of the multiple vaccines on the pediatric immunization schedule have been 
conducted, but to our knowledge no analyses of the cost-effectiveness of vaccinations 
included in the adult vaccination schedule has been done. The adult immunization standards 
of practice emphasize the need for providers to assess adult patients for all vaccines 
recommended by ACIP. This review provides information for providers regarding the adult 
vaccination schedule and the cost-effectiveness of recommended vaccines, with the objective 
of addressing potential limitations in awareness of the cost-effectiveness of vaccines 
recommended for adults. To meet this objective, we conducted a systematic review of the 
research literature since 1980, collecting and summarizing the cost-effectiveness findings 
related to vaccinations included in the U.S. adult vaccine schedule.
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2. Methods
We identified publications that estimated cost-effectiveness or economic value by directly 
comparing a vaccination strategy to a non-vaccination strategy among adult populations in 
the U.S. or Canada. This study searched online research literature databases, identified 
relevant publications, and analyzed the cost-effectiveness findings related to adult 
vaccinations.
This review focused on six vaccine groups: influenza, pneumococcal, HPV, HZ, Td/Tdap, 
and hepatitis B. We included HPV vaccinations even though that vaccine provides the 
greatest benefit when administered at age 11 or 12 years, as recommended by ACIP [17]. 
However, as of 2016 only 43% of adolescents were up to date on HPV vaccination [18], 
leaving many young adults unvaccinated or under-vaccinated and at risk of HPV-related 
cancers that occur predominantly during adulthood, such as cervical, penile, vaginal, and 
head and neck cancers [19]. We focused on these vaccines because they are routinely 
recommended for adults.
2.1. Search criteria
We conducted a systematic search of medical and economic research literature contained in 
four electronic databases: PubMed, Embase, Cochrane Libraries (Economic Evaluations), 
and EconLit. Our search included records from 1980 to 2016. We included studies as early 
as 1980 to capture some of the earliest economic research on vaccines in the U.S. [20,21]. 
To identify relevant economic evaluations, we included “cost-effectiveness” or “cost-utility” 
in our search terms. To identify vaccine-related publications, we included “vaccine,” 
“vaccination,” or “immunization” in our search terms. The economic and vaccine-related 
search terms were combined with additional terms designed to identify each vaccine or 
VPD. The terms to identify each vaccine group included “tetanus,” “diphtheria,” “pertussis,” 
“Td,” or “Tdap” for tetanus-diphtheria-pertussis vaccinations; “HPV” or “human 
papillomavirus” for e HPV vaccinations; “herpes zoster,” “zoster,” or “shingles” for herpes 
zoster vaccinations; “hepatitis B” for hepatitis B vaccinations; “influenza” or “flu” for 
influenza vaccinations; and “pneumococcal” for pneumococcal vaccinations. The complete 
set of electronic database search results and search terms is summarized in the appendix. 
During the review process, we consulted with subject matter experts in the area of each 
vaccine group and VPD to identify additional publications to include. We also investigated 
citations found in literature reviews that focused on adult vaccine cost-effectiveness [12,22–
33] to identify any additional publications.
2.2. Exclusion criteria and full text review process
Following the electronic database search results, we identified and excluded duplicate 
publications. The remaining publications and those identified through subject matter experts 
or referenced in other publications were subjected to a title and abstract review. During the 
title and abstract reviews, publications were excluded if the publication (1) did not 
Appendix. Supplementary material
Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2018.11.056.
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investigate a U.S. or Canadian population; (2) conducted an economic evaluation that was 
not a cost-effectiveness or cost-utility analysis, such as a cost-of-illness study; (3) focused 
exclusively on vaccinating children, defined as 17 years old or younger; (4) was written in a 
non-English language; and/or (5) was a review article, a letter to the editor, a commentary, or 
a conference presentation only.
Two independent reviewers conducted the full text review and data abstraction for all 
remaining publications using a standardized data abstraction form. Any initial differences in 
the two reviews were documented, discussed, and resolved. During the full text review, 
additional publications were excluded if the publications did not provide an adult-only, “no 
vaccination” comparator scenario that allowed for estimation of a cost-effectiveness ratio 
comparing adult vaccination to a scenario of no adult vaccination. If a publication reported 
the cost-effectiveness of an age group that included children (such as the cost effectiveness 
of HPV vaccination for ages 13–26 years), but did not report the cost-effectiveness 
specifically for an adult-only age group (such as ages 18–26 years), the publication would be 
excluded. Among the publications that were fully abstracted, several reported more than one 
cost-effectiveness ratio that were relevant to the adult vaccinations. In these cases, multiple 
cost-effectiveness ratios, or outcomes, were abstracted.
We did not conduct quality assessments of the studies we reviewed, owing to challenges 
such as the substantial diversity of diseases prevented by adult vaccination. However, all 
studies included in the full text review of this study did meet minimum standards of 
technical quality, including the presentation of sufficient detail to calculate a cost-
effectiveness ratio for an adult vaccination strategy. In addition, we used the number of 
citations in the literature as a proxy measure for study quality and importance. The quality of 
a study has been found to be a predictor for number of citations [34]. According to the 
Scopus database on research literature citations, the studies included in our final sample 
have been cited by the literature a total of 5961 times, with an average per study of 77 
(median = 36, interquartile range = 17–93). Citation counts for each study are included in 
the appendix.
2.3. Analysis
Outcomes were categorized according to vaccine group and type of vaccinations. The two 
types of vaccinations that were considered included age-based vaccinations and medical 
indication-based vaccinations. Age-based vaccinations are those given on the basis of age 
level, including the elderly. Medical indication-based vaccinations are given based on other 
indications, such as comorbidity or status as a health care worker. Health economic analyses 
can utilize a number of different outcome metrics [35,36]. The types of outcome metrics 
included cost-benefit measures, such as net benefit or total social cost, cost-savings, cost per 
case prevented, cost per life saved, cost per life-year saved, and cost per quality-adjusted 
life-year (QALY) saved. To assess cost-savings and cost-effectiveness, we focused our 
analyses on the outcomes that were either completely monetized, such as cost-benefit 
measures, or measured as cost per life-year gained or cost per QALY saved. In some 
publications, the total costs and total outcomes were presented for the vaccination and “no 
vaccination” scenario but the cost-effectiveness ratio(s) of interest to this review were not 
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explicitly presented. In these cases, the abstractors computed the cost-effectiveness ratio(s) 
from reported total costs and total outcomes.
For outcomes that utilized cost-benefit measures, cost per life-year saved, or cost per QALY 
saved, we calculated the percent of outcomes that indicated vaccinations were cost-saving. 
Specifically, a cost-saving outcome was one in which the benefits exceeded the cost (i.e., 
savings) in a cost-benefit measure, the cost per life-year saved was less than $0, or the cost 
per QALY gained was less than $0.
Among outcomes that utilized cost per QALY saved, we presented each outcome 
graphically, stratified by vaccine group and by type of vaccination. In the text we also 
reported the percentage of outcomes that fell within three different $/QALY thresholds of 
$50,000/QALY, $100,000/QALY, and $300,000/QALY. Because no single $/QALY 
threshold is utilized for health-related decision-making, we present results utilizing three 
different thresholds to provide a range for assessing overall trends in cost-effectiveness. The 
presentation of results across multiple cost-effectiveness thresholds is supported by recent 
recommendations by the Second Panel on Cost-Effectiveness in Health and Medicine 
[35,37]. In cases where the abstracted outcome was a range of values, we utilized the lower 
end of the range to assess the percentage of outcomes that fall below a given threshold. Both 
the cost-saving and the $/QALY analyses were stratified by vaccine group and by study 
population. All costs were adjusted to 2016 U.S. dollars using the consumer price index [38] 
and, for publications reporting values in Canadian dollars, the US-Canadian exchange rate 
[39].
3. Results
Our search strategy identified 1688 publications (Fig. 1). After removing duplicates and 
excluding for relevance, 78 publications, including 25 influenza, 9 Td/Tdap, 7 HZ, 18 
pneumococcal, 9 hepatitis B, 9 HPV, and 1 publication including both influenza and 
pneumococcal vaccines, were fully abstracted and incorporated into the final analysis.
3.1. Number and type of outcomes identified
The 78 abstracted publications yielded 161 outcomes (Table 1). All the identified outcomes 
from the publications in the final set of records are summarized in the appendix [66–133]. 
The percent of outcomes associated with age-based vaccination recommendations by 
vaccine group was 75 for influenza, 62 for pneumococcal, 74 for HPV, 100 for HZ, and 72 
for Td/Tdap. All outcomes for hepatitis B focused on populations that have indication-based 
recommendations (e.g. diabetes, healthcare workers, injection drug users, etc.). Across all 
vaccine groups we investigated, the most common outcome measure was cost per QALY 
saved. Other outcomes identified were cost per case prevented, found in 10% of influenza 
outcomes and 42% of hepatitis B outcomes; and cost per life-year saved, found in 22% of 
Td/Tdap outcomes and 11% of hepatitis B outcomes (Table 1).
3.2. Outcomes that evaluate the cost savings of adult vaccinations
For the outcomes assessing age-based vaccinations, the percent of outcomes that reported 
cost-savings were 56 for influenza, 31 for pneumococcal, and 23 for Td/Tdap vaccinations 
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(Table 2). For the outcomes assessing indication-based vaccinations, the percent of outcomes 
that reported cost-saving values were 46 for influenza, 44 for pneumococcal, 40 for Td/
Tdap, and 37 for hepatitis B vaccinations. No cost-saving outcomes were identified in 
publications assessing HPV or HZ vaccinations for either age-based or indication-
vaccinations (Table 2).
3.3. Outcomes that evaluate the cost per QALY saved of adult vaccinations
Among outcomes reported as cost per QALY saved, many publications across all adult 
vaccinations estimated costs per QALY saved that might be considered cost-effective 
[40,41]. Every cost per QALY saved outcome that was identified is presented graphically, 
with a panel for outcomes that assessed age-based vaccinations (Fig. 2a) and another panel 
for outcomes that assessed indication-based vaccinations (Fig. 2b). For outcomes assessing 
age-based vaccinations, the percent indicating any cost-effectiveness estimate equal to or 
below $50,000/QALY were 100 for influenza, 78 for pneumococcal, 54 for HPV, 36 for HZ, 
and 30 for Td/Tdap vaccinations. For outcomes assessing indication-based vaccinations, the 
percent indicating any cost-effectiveness estimate equal to or below $50,000/QALY were 73 
for influenza, 77 for pneumococcal, 40 for HPV, 25 for Td/Tdap, and 38 for hepatitis B 
vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of 
outcomes indicating a cost per QALY of ≤$100,000 was 82 for influenza, 100 for 
pneumococcal, 69 for HPV, 71 for HZ, and 50 for Td/Tdap vaccinations. Across all 
vaccinations, substantial percentages of outcomes assessing age-based or indication-based 
vaccinations indicated cost-effectiveness that were equal to or below $300,000/QALY (Fig. 
2). As a summary measure, when looking across all vaccine groups and including both the 
age-based and the indication- based outcomes that we collected in our review, we found 32% 
of all outcomes indicated that adult vaccination was cost-saving. Looking at costs per QALY 
saved, 80% of outcomes indicated a cost per QALY of ≤$100,000 and 60% of outcomes 
indicated a cost per QALY of ≤$50,000.
4. Discussion
This systematic review provides an updated synthesis of the cost-effectiveness research 
literature on adult vaccinations, with a focus on estimates of cost-effectiveness that compare 
adult vaccination to “no vaccination”. Consistent with previous reviews, we found that adult 
vaccinations have a favorable cost-effectiveness profile in the majority of the outcomes we 
reviewed. Indeed, a substantial portion of influenza, pneumococcal, and Td/Tdap related 
outcomes estimated appear to be cost-saving. For influenza and pneumococcal vaccinations, 
the majority of outcomes reported either cost savings or cost-effectiveness ratios ≤$50,000/
QALY. For HPV and HZ vaccinations, the majority of outcomes reported cost-effectiveness 
ratios ≤$100,000/QALY. While our findings reflect favorable cost-effectiveness among 
outcomes for most vaccine groups, we do find a small number of exceptions to this overall 
trend. These exceptions can be understood based on particular underlying assumptions and 
modeling choices that contribute to a cost-effectiveness estimate that may be higher than 
expected. In one case, particular scenarios investigating Tdap vaccination utilized an 
incidence assumption for pertussis that is low relative to the incidence used in other 
scenarios of the same study [42–44]. In another case, scenarios were designed to investigate 
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patient groups that are not currently recommended for vaccinations. Examples include 
hepatitis B vaccinations of diabetics who are 60 years and older [45], HPV vaccination of 
persons older than 26 years [46], and HZ vaccination with the zoster live vaccine of persons 
aged 50–59 [47]. These outcomes tend to report higher cost-effectiveness ratios because the 
assumptions inherent in these scenarios represent populations or conditions that have lower 
risks for VPD or VPD-associated costly outcomes. Our overall findings would demonstrate 
even more favorable overall cost-effectiveness if we restricted our sample to outcomes that 
more exclusively investigate ACIP vaccination recommendations. The broad finding of our 
study that adult vaccinations exhibit favorable cost-effectiveness appears to be consistent, 
across age-based and indication-based vaccinations.
The percentage of outcomes using a cost per QALY saved is highest among vaccines that 
were more recently approved and recommended (Table 1). Greater than 90% of outcomes 
assessed cost per QALY among both HZ and HPV vaccination outcomes. In particular, 
influenza and hepatitis B vaccination outcomes contained a more diverse set of outcome 
types, and the influenza and hepatitis B vaccines have been in use for much longer than HZ 
and HPV vaccines. Older publications in our sample tended to include more outcomes that 
were measured in strictly monetary terms (e.g., net benefit) or as cost per cases prevented. 
This trend seems to reflect the growing influence and prevalence of the QALY as a health 
measure in CEAs. Variation in cost per QALY within a particular vaccine group and 
recommendation type can be observed in Fig. 2. This variation can be due to a wide range of 
potential modeling choices. Some of those modeling choices may include the severity of an 
influenza season, the effect of herd immunity on HPV or pneumococcal transmission, as 
well as changes in vaccine technology.
While cost-effectiveness estimates appear to be generally favorable, vaccination coverage 
among adults for whom vaccination is recommended remains low for influenza (45% among 
adults ≥19 - years old), pneumococcal (23% among adults 19–64 at increased risk), Td/Tdap 
(23% among adults ≥19 years old), HZ (31% among adults >60 years old), and hepatitis B 
(25% among adults ≥19 years old) [3]. Lower vaccination coverage rates have been found 
among minority racial and ethnic groups compared to non-Hispanic white populations 
[48,49]. In addition, differences in vaccination coverage rates across states suggest that local 
factors may be an important source of vaccination coverage rates disparities [50]. A number 
of additional obstacles to high vaccination coverage among adults have been documented. 
Patient perceptions about infection risks and vaccine efficacy can influence vaccine uptake 
[51]. Concerns regarding vaccination payments have been reported as major barriers to adult 
vaccination implementation by healthcare providers, including family physicians, internists 
and obstetricians and gynecologists [52,53]. Vaccination billing and coding errors may be 
responsible for perceptions of inadequate payment [54]. Medicaid payments for adult 
vaccinations vary substantially by state and may be a barrier to vaccinating adults on 
Medicaid in some states [54,55], especially pregnant women where substantially lower Tdap 
coverage has been documented for those on Medicaid compared to private insurance [56,57]. 
Coverage of some vaccines as part of Medicare Part B (influenza, pneumococcal, Td for 
wound treatment and hepatitis B vaccine for persons with high risk conditions) and 
Medicare Part D (e.g., Td, Tdap, and hepatitis B for prevention, and zoster vaccination) and 
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payment complexities are also provider-level barriers that must be considered during 
implementation and planning [52,58].
Other preventive services, such as hypertension screening and breast/colorectal cancer 
screening, appear to have similar cost-effectiveness profiles as adult vaccinations [59–61], 
however these services appear to be given greater priority during clinical practice. A survey 
of internal medicine and family medicine physicians suggested that physicians had a lower 
priority for HZ and Td/Tdap vaccinations than other age-relevant preventive services [9]. For 
vaccinations, provider awareness of the economic value may be particularly important 
because the influence of a provider recommendation has been found to be important for 
patients’ decision to receive a vaccine [11]. These challenges are particularly unfortunate in 
light of the main finding of this study, which is that the majority of outcomes we 
investigated found attractive cost-effectiveness estimates for adult vaccinations. Efforts to 
improve healthcare providers and health systems’ awareness of the cost-effectiveness of 
adult vaccines may prompt efforts to improve the implementation of vaccination 
recommendations and reduce missed opportunities for adult vaccinations.
4.1. Limitations
Our analysis is subject to limitations. While we made every reasonable effort to identify and 
utilize all cost-effectiveness and economic evaluation publications related to adult 
vaccinations, publications may have been missed. In particular, research that was not 
indexed by the electronic research literature databases that we used in our searches may also 
have been missed. Given that our searches primarily identified studies in the published 
research literature, publication-bias may have influenced our results. Because all the 
outcomes from any particular study may be correlated, the abstraction of more than one 
outcome from a study could lead to a bias. Our abstraction of cost-effectiveness outcomes 
from each publication intended to best represent the majority of currently available vaccines 
for adults. However, additional adult vaccines have become available since our electronic 
database searches were conducted, such as for the new adjuvant vaccine for HZ [62]. While 
we did not identify a published, peer-reviewed cost-effectiveness on this new HZ vaccine at 
the time of our literature search, analyses provided to the Advisory Committee on 
Immunization Practices suggests a favorable cost effectiveness profile for the new HZ 
vaccine when compared to “no vaccination” [63]. Our review specifically targeted 
publications that assessed vaccination versus “no vaccination”, so we did not review the 
numerous publications and outcomes that only assessed cost-effectiveness comparing two or 
more vaccination strategies, or comparing two or more vaccines. Due to the relatively broad 
scope of this review, we were also unable to assess the overall quality of the publications or 
to assess the quality and influence of any specific inputs. Finally, the cost components of the 
outcomes investigated by our study captured a mixture of medical and non-medical costs. 
The inflation adjustment we applied to these outcomes did not account for differing rates of 
price increases among medical and non-medical costs.
4.2. Conclusions
Adult vaccinations prevent substantial morbidity, disability and death among adults and have 
cost-effectiveness profiles that are considered favorable across multiple age- and medical-
Leidner et al. Page 8
Vaccine. Author manuscript; available in PMC 2020 January 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
indication-based recommendations. Efforts to increase the implementation of adult 
vaccination recommendations, including communication of the economic value of adult 
vaccines to providers and patients and addressing barriers to implementation, are needed.
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Fig. 1. 
Cascade diagram of search results and exclusion criteria from a systematic review of adult 
vaccination cost-effectiveness and economic evaluation publications. Note (s): Td/Tdap = 
tetanus-diphtheria-pertussis; Pneumo = pneumococcal; Hep B = hepatitis B; HPV = human 
papillomavirus; HZ = herpes zoster.
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Fig. 2. 
Summary of cost-effectiveness results on (a) age-based vaccinations and (b) indication-
based vaccinations, stratified by vaccine group, from a systematic review of adult 
vaccination cost-effectiveness and economic evaluation publications. Note(s): Each data 
point or range represents one outcome that assessed cost-effectiveness in terms of cost per 
QALY saved. The data points are partially transparent such that darker points represent two 
or more observations. Each column represents a single study, e.g., multiple data points in a 
single column are different cost-effectiveness ratios or ranges taken from the same study. 
The data points with error bars or lines indicate outcomes where a range of cost-
effectiveness was abstracted and in these cases the midpoints of the ranges are illustrated 
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with the data point. In the age-based vaccinations, there were no hepatitis B studies, and in 
the indication-based studies there were no herpes zoster studies. To simplify presentation, 
cost-effectiveness ratios that were cost-saving (where costs were less and outcomes were 
greater than the “no vaccination” comparator) are located on the x-axis where $/QALY 
equals zero. Also to simply presentation, cost-effectiveness ratios that were greater than 
$500,000 per QALY saved are indicated with an “X” on the figure.
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lic
at
io
ns
 ro
w
 s
u
m
s 
to
 7
9 
in
ste
ad
 o
f 7
8.
b T
he
 n
um
be
r o
f o
ut
co
m
es
 is
 g
re
at
er
 th
an
 th
e 
nu
m
be
r o
f p
ub
lic
at
io
ns
 b
ec
au
se
 e
ac
h 
pu
bl
ic
at
io
n 
co
ul
d 
co
nt
ai
n 
m
ul
tip
le
 o
ut
co
m
es
, o
r e
co
no
m
ic
 v
al
ue
 e
sti
m
at
es
, t
ha
t w
er
e 
re
le
v
an
t t
o 
ad
ul
t v
ac
ci
na
tio
ns
.
c T
hi
s o
ut
co
m
e 
ty
pe
 o
nl
y 
in
cl
ud
es
 o
ut
co
m
es
 fr
om
 o
ne
 p
ub
lic
at
io
n 
[6
4]
 th
at 
rep
or
ted
 as
 co
sts
 pe
r p
ers
on
 va
cc
in
at
ed
 w
hi
le
 ex
cl
ud
in
g 
th
e 
co
sts
 o
f v
ac
ci
ne
s. 
Th
e 
m
ajo
rity
 of
 pu
bli
cat
ion
s r
ep
ort
ing
 ou
tco
me
s a
s 
co
st
s 
(or
 sa
v
in
gs
) p
er 
pe
rso
n v
ac
ci
na
te
d 
di
d 
in
clu
de
 
th
e 
co
sts
 o
f v
ac
ci
ne
 m
at
er
ia
ls 
an
d 
ad
m
in
ist
ra
tio
n,
 w
hi
ch
 w
e 
co
ns
id
er
ed
 to
 b
e 
a 
co
st-
 b
en
ef
it 
m
et
ric
, o
r a
 $ 
(ne
t b
en
efi
t o
r o
th
er
 C
BA
 m
et
ric
).
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Ta
bl
e 
2
Su
m
m
ar
y 
of
 c
os
t-s
av
in
gs
 a
nd
 c
os
t-e
ffe
ct
iv
en
es
s 
re
su
lts
 fr
om
 a
 sy
ste
m
at
ic
 re
v
ie
w
 o
f a
du
lt 
va
cc
in
at
io
n 
co
st-
ef
fe
ct
iv
en
es
s 
an
d 
ec
on
om
ic
 ev
al
ua
tio
n 
pu
bl
ic
at
io
ns
, s
tra
tif
ie
d 
by
 v
ac
ci
ne
 g
ro
up
.
Ty
pe
 o
f v
a
cc
in
at
io
n
C
os
t-s
av
in
gs
 re
su
lts
Va
cc
in
e 
gr
o
u
p
In
flu
en
za
Pn
eu
m
oc
oc
ca
l
H
um
an
pa
pi
llo
m
av
ir
us
H
er
pe
s
zo
st
er
Te
ta
nu
s-
di
ph
th
er
ia
-
pe
rt
us
sis
H
ep
at
iti
s
B
A
ge
-b
as
ed
 v
ac
ci
na
tio
ns
O
ut
co
m
es
 u
sin
g 
m
on
et
ar
y 
un
its
, $
/LY
,
 
o
r 
$/Q
AL
Y
32
a
26
a
14
15
13
0
Pe
rc
en
ta
ge
 o
f o
ut
co
m
es
 in
di
ca
tin
g 
co
st-
sa
v
in
gs
56
31
0
0
23
Pe
rc
en
ta
ge
 o
f s
tu
di
es
 in
di
ca
tin
g 
co
st-
sa
v
in
gs
b
56
15
0
0
29
In
di
ca
tio
n-
ba
se
d
O
ut
co
m
es
 u
sin
g 
m
on
et
ar
y 
un
its
, $
/LY
,
 
o
r 
$/Q
AL
Y
13
16
5
0
5
19
v
ac
ci
na
tio
ns
Pe
rc
en
ta
ge
 o
f o
ut
co
m
es
 in
di
ca
tin
g 
co
st-
sa
v
in
gs
46
44
0
40
37
Pe
rc
en
ta
ge
 o
f s
tu
di
es
 in
di
ca
tin
g 
co
st-
sa
v
in
gs
b
39
57
0
50
46
N
ot
e(s
): 
QA
LY
 =
 q
ua
lit
y-
ad
jus
ted
 lif
e-y
ear
; L
Y
 =
 li
fe
-y
ea
r.
a C
os
t-s
av
in
gs
 c
ou
ld
 n
ot
 b
e 
as
ce
rta
in
ed
 fo
r o
ne
 o
ut
co
m
e 
re
la
te
d 
to
 in
flu
en
za
 a
ge
-b
as
ed
 v
ac
ci
na
tio
ns
 [6
4]
.
b F
o
r 
th
es
e 
re
su
lts
, w
e 
co
m
bi
ne
d 
al
l a
bs
tra
ct
ed
 o
ut
co
m
es
 in
to
 a
 si
ng
le
 o
ut
co
m
e 
fo
r e
ac
h 
stu
dy
.
 
A
s a
n 
ex
am
pl
e,
 P
ro
ss
er
 e
t a
l. 
20
11
 [6
5]
 ha
d t
wo
 a
bs
tra
ct
ed
 o
ut
co
m
es
, o
ne
 th
at
 w
as
 n
o
t c
os
t-
sa
v
in
g:
 $2
7,0
00
 to
 
$1
70
,00
0 p
er 
QA
LY
 sa
v
ed
 a
m
on
g 
lo
w
-r
isk
 a
du
lts
 a
ge
d 
18
 y
ea
rs
 a
nd
 o
ld
er
,
 
an
d 
on
e 
th
at
 w
as
 c
o
st
-s
av
in
g 
(le
ss 
tha
n $
0 p
er 
QA
LY
 sa
v
ed
) a
mo
ng
 hi
gh
-ri
sk
 ad
ult
s a
ge
d 1
8–
64
. T
he
se 
tw
o
 a
bs
tra
ct
ed
 o
ut
co
m
es
 
w
er
e 
co
m
bi
ne
d 
in
to
 a
 p
ro
po
rti
on
al
 v
al
ue
 o
f 0
.5
 fo
r t
hi
s s
tu
dy
.
 
Th
e 
pr
op
or
tio
na
l v
al
ue
s f
or
 e
ac
h 
stu
dy
 w
er
e 
th
en
 c
om
bi
ne
d 
ac
ro
ss
 v
ac
ci
ne
 g
ro
up
s a
nd
 ty
pe
 o
f v
ac
ci
na
tio
ns
.
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